Originally published by our sister publication Clinical Oncology News
The Community Oncology Alliance (COA) has filed a lawsuit on behalf of its members and the patients they serve against the Department of Health and Human Services (HHS) to overturn a recent change in federal health policy restricting cancer care practices from delivering drugs to patients. The suit calls the change in policy an unconstitutional and dangerous display of government overreach that presents real and irreparable injury to patients.
The lawsuit was filed in the U.S. District Court District of Columbia. The COA’s suit is in response to a Frequently Asked Questions (FAQ) document issued by the Centers for Medicare & Medicaid Services (CMS) stating that it is a violation of the Stark law for independent practices to deliver oral cancer medications to their patients, even if a caregiver picks up a drug for a patient. The guidance was released ahead of the end of the COVID-19 public health emergency (PHE) on May 11, 2023.
“HHS has blatantly and clearly overreached with this FAQ and cancer patients are suffering because of it. COA filed this lawsuit because we cannot let the government simply make unconstitutional rule changes whenever it wants,” said Ted Okon, the executive director of COA. “By allowing this FAQ to silently become official policy, CMS has courted disaster for cancer patients and others with serious diseases across the country. The clinical best practices and procedures for patient care, that practices followed forever, are now being upended by bureaucratic edict and putting Medicare seniors at risk.”
The case notes that since the issuance of the FAQ, patients with cancer across the country have faced disruptions to their care. In some cases, patients have been forced by CMS to rely on pharmacy benefit manager mail order pharmacies for their treatments, which COA has long noted are prone to delays, denials and issues with delivery. The change has been particularly problematic for patients too sick to pick up their drugs, especially in rural or underserved areas, and low-income patients who are now forced to travel, often having to use public transportation to return to the clinic to receive their drug therapies each month.
COA believes that the rule change quietly issued through an FAQ on a website violates the federal rulemaking process required for such a “substantive amendment” to existing rules, in addition to the 10th Amendment to the U.S. Constitution. The Medicare Act and Administrative Procedure Act require formal notice and comment periods so that stakeholders can be adequately notified and allowed to express their concerns before such major changes to existing rules. Further, the 10th Amendment should protect those states with preexisting physician-dispensed medication mailing rules from interference by the federal government.
The case is Community Oncology Alliance v. Becerra et al., case number 1:23-cv-02168, in the U.S. District Court for the District of Columbia. COA is represented by Jonathan Levitt, Jason Silberberg and Matthew Modafferi of the law firm Frier Levitt LLC.
Read the full filing at https://mycoa.s3.amazonaws.com/COA_StarkDrugDelivery_HHS-CMS_Lawsuit.pdf.
—Clinical Oncology News Staff
Based on a press release from the COA.